Table 2. AFT Model to Predict Progression-Free Survival Fig 2. Effect of GETNE-TRASGU (Spanish Group of Neuroendocrine and Endocrine Tumors–Treated With Analog of Somatostatin in ...

Foundation successfully hosted its 4th ICPO Forum for Theranostics in Precision Oncology on May 15 & 16, 2025 in Garching ...

Q1 2025 Earnings Call Transcript May 13, 2025 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.55, expectations were $0.42. Operator: Good day, ladies and gentlemen, and welcome to the ...

Over 220 experts from around the globe came together to shape the future of radiotheranostics for better cancer patient outcomes Wiesbaden - May 26, 2025 - The International Centers for Precision ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are uncommon and heterogeneous neoplasms ... Only two patients underwent subtotal pancreatectomy (Table 1). Among the 39 patients who had a distal ...

Several strategies have been used to inhibit VEGF signaling (Table). Broadly ... hepatocellular carcinoma, colorectal cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, soft ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...